CTOs on the Move

Kinnate

www.kinnate.com

 
Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations of marketed cancer therapies, such non-responsiveness or acquired and intrinsic resistance. Kinnate has two lead clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.kinnate.com
  • 12830 El Camino Real Suite 150
    San Diego, CA USA 92130
  • Phone: 858.299.4699

Executives

Name Title Contact Details

Funding

Kinnate raised $74.5M on 12/19/2019
Kinnate raised $98M on 08/26/2020

Similar Companies

Concentric Analgesics

Concentric Analgesics, Inc. is a private, biotechnology company focused on discovering and developing novel, non-opioid therapeutics for the management of acute and chronic pain.

Exalenz Bioscience

Exalenz Bioscience is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Selventa

Selventa is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

J. Craig Venter Institute (JVCI)

J. Craig Venter Institute (JVCI) is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunovant

Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.